Sugi Predict

Sugi Predict / Compounds / SCHEMBL985324

SCHEMBL985324

SCHEMBL985324

CC1=C(C)Oc2ccccc2C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 2/20 0.60
▸ MAOB P27338 2/20 0.60
▸ GAA P10253 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MAPKAPK2 P49137 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ OXTR P30559 1/20 0.32
▸ ABCG2 Q9UNQ0 1/20 0.32
▸ ITGB2 P05107 1/20 0.32
▸ ICAM1 P05362 1/20 0.32
▸ ITGAL P20701 1/20 0.32
▸ CYP1A2 P05177 1/20 0.31
▸ SETD7 Q8WTS6 1/20 0.31
▸ ACSL1 P33121 1/20 0.31
▸ DRD2 P14416 1/20 0.30
▸ DRD1 P21728 1/20 0.30
▸ DRD4 P21917 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8470353 0.77 MAOA (0.65) MAOAMAOBGAANPSR1MAPKAPK2
SCHEMBL22793041 0.76 MAOA (0.52) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL29378346 0.76 MAOA (1.00) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL30586075 0.76 MAOA (1.00) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL9339684 0.76 MAOA (1.00) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL4267 0.76 MAOA (1.00) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL23355281 0.74 MAOA (0.94) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL2478466 0.74 MAOA (0.94) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL11600668 0.74 MAOA (0.94) MAOAMAOBGAANPSR1MAPKAPK2
Xanthene SCHEMBL1673119 0.74 MAOA (0.94) MAOAMAOBGAANPSR1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087478-A1 HIF-1 Inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-08 — — US claimed
EP-0521099-A4 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY — 1993-10-20 — — EP claimed
EP-0521099-A1 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-01-07 — — EP claimed
WO-1991014694-A1 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1991-10-03 — — WO claimed
US-20240400784-A1 Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition LG CHEM, LTD. (KR) 2024-12-05 — — US disclosed
CN-114751913-B Chromone compound and preparation method and application thereof 云南中烟工业有限责任公司 2023-08-29 — — CN disclosed
CN-114685524-B Chromone compound and preparation method and application thereof 云南中烟工业有限责任公司 2023-07-14 — — CN disclosed
CN-114751913-A Chromone compound and preparation method and application thereof 云南中烟工业有限责任公司 2022-07-15 — — CN disclosed
CN-114685524-A Chromone compound and preparation method and application thereof 云南中烟工业有限责任公司 2022-07-01 — — CN disclosed
CN-111662301-B Benzisothiafuranolactone compound, preparation method and application thereof, and liquid aromatherapy containing benzisothiafuranolactone compound 云南民族大学 2022-05-20 — — CN disclosed
US-20220105054-A1 ABSORPTION ENHANCER OF CINNAMIC ACID DERIVATIVE YAMADA BEE COMPANY, INC. (JP) 2022-04-07 — — US disclosed
CN-110483536-B Tricyclic isoquinoline alkaloid compound extracted from sabina chinensis and application thereof 云南中烟工业有限责任公司 2022-03-11 — — CN disclosed
US-5605703-A REDUCE TOXICITY OF DRUG WHEN ADMINISTERED BY INJECTION LIPOTEC, S.A. (ES) 1997-02-25 — — US disclosed
WO-1996026934-A1 SYNTHESIS OF OPTICALLY ACTIVE CALANOLIDES A AND B AND ENANTIOMERS AND RELATED COMPOUNDS THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1996-09-06 — — WO disclosed
WO-1996026937-A1 PROKINETIC OXADIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 1996-09-06 — — WO disclosed
EP-0669919-A1 USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 1995-09-06 — — EP disclosed
EP-0655239-A1 Liposomes encapsulating doxorubicine LIPOTEC, S.A. (ES) 1995-05-31 — — EP disclosed
WO-1994012494-A1 USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 1994-06-09 — — WO disclosed
US-4510337-A REACTION OF PHENOLS WITH ISOPRENE OR 2,3-DIMETHYL-1,3-BUTADIENE IN THE PRESENCE OF PHOSPHORIC ACID PHILLIPS PETROLEUM COMPANY (US) 1985-04-09 — — US disclosed
US-4251537-A Hypotensive 3,4-dihydro-2,2-dimethyl-4-amino-2H-benzo[b]pyran-3-ols BEECHAM GROUP LIMITED (GB) 1981-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220105054-A1 ABSORPTION ENHANCER OF CINNAMIC ACID DERIVATIVE FABP2, SLC16A3, SLC16A7 MAOA 1289/4885MAOB 1063/4885GAA 3918/4885
US-20100087478-A1 HIF-1 Inhibitors HIF1AN, HIF1A, EGLN2 MAOA 3334/4885MAOB 2308/4885GAA 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.